OKYO Liabilities And Stockholders Equity from 2010 to 2025

OKYO Stock  USD 1.26  0.11  9.57%   
OKYO Pharma Liabilities And Stockholders Equity yearly trend continues to be very stable with very little volatility. Liabilities And Stockholders Equity is likely to drop to about 1.3 M. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal OKYO Pharma's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2008-03-31
Previous Quarter
5.2 M
Current Value
5.2 M
Quarterly Volatility
14.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check OKYO Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OKYO Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.3 K, Interest Expense of 1.3 M or Selling And Marketing Expenses of 1.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0254 or Days Sales Outstanding of 0.0. OKYO financial statements analysis is a perfect complement when working with OKYO Pharma Valuation or Volatility modules.
  
Check out the analysis of OKYO Pharma Correlation against competitors.

Latest OKYO Pharma's Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of OKYO Pharma Ltd over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. OKYO Pharma's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OKYO Pharma's overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
597.7.1M4.3M5.2M1.5M1.4M1.3M1087%-39%21%-70%-10%-5%100%
       Timeline  

OKYO Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean17,525,228
Geometric Mean6,966,908
Coefficient Of Variation103.89
Mean Deviation16,689,988
Median7,091,322
Standard Deviation18,206,967
Sample Variance331.5T
Range46.6M
R-Value(0.85)
Mean Square Error101.1T
R-Squared0.72
Significance0.000037
Slope(3,234,569)
Total Sum of Squares4972.4T

OKYO Liabilities And Stockholders Equity History

20251.3 M
20241.4 M
20231.5 M
20225.2 M
20214.3 M
20207.1 M
2019597.4 K

About OKYO Pharma Financial Statements

OKYO Pharma investors utilize fundamental indicators, such as Liabilities And Stockholders Equity, to predict how OKYO Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity1.4 M1.3 M
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out the analysis of OKYO Pharma Correlation against competitors.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.